Amycretin
An investigational GLP-1 and amylin receptor agonist being developed in both oral and subcutaneous forms. It entered Phase 3 development in 2026 and is not approved.
- Half-life
- 7.0 d
- Out of system
- ~5 weeks
- Route
- Subcutaneous
- Level
- Advanced
Long-acting — weekly dosing keeps levels steady. After the last dose, roughly 97% has cleared in ~5 weeks (five half-lives) — the window that matters for washouts, bloodwork and surgery.
What Amycretin is used for
- Combines GLP-1 and amylin agonism for strong appetite suppression and weight loss
- Being developed in both oral and subcutaneous forms for dosing flexibility
- Early data suggest competitive weight-reduction potential
How it's typically used
Trial range: doses are titrated per study protocol in ongoing oral and subcutaneous trials, as reported in the literature.
What to watch for
- GI side effects are common and titration is required to manage tolerability
- Long-term safety is not yet established given early-stage development
- Investigational; entered Phase 3 in 2026 and is not approved
Common questions
- What is the half-life of Amycretin?
- Amycretin has an approximate elimination half-life of 7.0 d. Long-acting — weekly dosing keeps levels steady.
- How long does Amycretin stay in your system?
- Roughly 97% of a dose has cleared after five half-lives — about ~5 weeks for Amycretin. That is the window that matters for washouts, bloodwork and surgery.
- How is Amycretin taken?
- Amycretin is typically administered by the subcutaneous route. Trial range: doses are titrated per study protocol in ongoing oral and subcutaneous trials, as reported in the literature.
- What are the risks of Amycretin?
- GI side effects are common and titration is required to manage tolerability Long-term safety is not yet established given early-stage development Investigational; entered Phase 3 in 2026 and is not approved
About GLP-1 & weight loss
- What they are
- Incretin analogues — GLP-1 and dual/triple agonists. They slow stomach emptying and act on appetite centres in the brain, so you eat less without white-knuckling it.
- How they're run
- One subcutaneous shot a week for most, on the same day each week. Doses climb in steps every four weeks; that slow titration is what keeps side effects tolerable.
- What to watch
- Nausea, constipation, and reflux are near-universal in the first month. Muscle is lost alongside fat unless you keep protein high and keep lifting. Tell any surgeon or anaesthetist you are on one.
Full guide
Amycretin: A Tracking Guide for a GLP-1 and Amylin Agonist
A neutral, harm-reduction guide to amycretin, an investigational GLP-1/amylin agonist in oral and injectable forms, entering Phase 3.
Other glp-1 & weight loss
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.